Pharmacological Perturbation of the Golgi Checkpoint Synergizes with Apoptotic Priming to Selectively Induce Tumor Cell Death. (PubMed, Cells) - Oct 17, 2026 - "We therefore used SP600125 (SP) together with MK1775 (MK) as a previously characterized pharmacological platform and screened for compounds capable of further sensitizing these cells to death. This screen identified Navitoclax, a BCL-2/BCL-XL inhibitor, as the strongest enhancer of the SP+MK response...Annexin V analysis confirmed apoptosis rather than mitotic slippage. Together, these findings identify a tumor-selective vulnerability linked to Golgi checkpoint disruption and support a therapeutic strategy combining Golgi checkpoint inhibition, forced mitotic entry and apoptotic priming to selectively eliminate cancer cells."
Journal • Oncology • ANXA5 • BCL2 • BCL2L1
|
|
Antonino Colanzi; Fabiola Mascanzoni; Roberta Iannitti
|